Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Dapagliflozin 10 mg vs Forxiga in Healthy Thai Volunteers
NCT06233045Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bio-innova. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration at 48.00 hours, Maximal measured plasma concentration at 48.00 hours and 1 more. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06233045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233045.